Wave gets another shot at Huntington’s
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Novartis’s canakinumab cancer test approaches
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
Go or no go? Oncology decisions ahead for the FDA
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
The year immuno-oncology could break into perioperative settings
Keytruda could soon be approved in periadjuvant breast cancer, but adjuvant lung cancer, a bigger setting, is 2021’s big showdown.
Go or no go? New Year approval decisions for the US regulators
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
